Farallon Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Farallon Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$231K	Hold	16,000	–	–	﹤0.01%	133
2025 Q4	$228K	Hold	16,000	–	–	﹤0.01%	127
2025 Q3	$126K	Hold	16,000	–	–	﹤0.01%	133
2025 Q2	$91.7K	Hold	16,000	–	–	﹤0.01%	133
2025 Q1	$131K	Hold	16,000	–	–	﹤0.01%	131
2024 Q4	$151K	Hold	16,000	–	–	﹤0.01%	136
2024 Q3	$171K	Hold	16,000	–	–	﹤0.01%	146
2024 Q2	$159K	Hold	16,000	–	–	﹤0.01%	147
2024 Q1	$188K	Hold	16,000	–	–	﹤0.01%	149
2023 Q4	$227K	Hold	16,000	–	–	﹤0.01%	122
2023 Q3	$195K	Buy	+16,000	New	+$206K	﹤0.01%	131
2021 Q2	–	Sell	-100,000	Closed	-$988K	–	306
2021 Q1	$988K	Sell	100,000 -1,150,000	-92%	-$17.8M	﹤0.01%	227
2020 Q4	$28.9M	Buy	+1,250,000	New	+$25.6M	0.17%	82
2018 Q3	–	Sell	-3,655,000	Closed	-$57.1M	–	105
2018 Q2	$57.1M	Buy	3,655,000 +174,000	+5%	+$2.63M	0.35%	47
2018 Q1	$52.4M	Buy	3,481,000 +700,000	+25%	+$10.7M	0.36%	48
2017 Q4	$40M	Sell	2,781,000 -2,300,055	-45%	-$31.6M	0.33%	44
2017 Q3	$76.6M	Buy	5,081,055 +2,081,055	+69%	+$27.5M	0.68%	37
2017 Q2	$30.2M	Buy	+3,000,000	New	+$24.1M	0.31%	48

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Farallon Capital Management's FOLD Position: Q1 2026 in Review

Farallon Capital Management held its Amicus Therapeutics (FOLD) position steady in Q1 2026 at 16,000 shares worth $231K. The position accounts for ﹤0.01% of the portfolio, ranked #133.

Farallon Capital Management first reported a position in FOLD in Q2 2017 and has held it in 18 quarters since. The position peaked at $76.6M in Q3 2017. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Farallon Capital Management held 16,000 shares of Amicus Therapeutics worth $231K as of Q1 2026.
Farallon Capital Management left its Amicus Therapeutics share count unchanged in Q1 2026.
Amicus Therapeutics made up ﹤0.01% of Farallon Capital Management's portfolio in Q1 2026, its #133 holding.
Farallon Capital Management first reported a position in Amicus Therapeutics in Q2 2017 and has held it in 18 quarters since.
Farallon Capital Management's Amicus Therapeutics position peaked at $76.6M in Q3 2017.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.